CSCs were first reported in liquid tumors, such as leukemias, with CD34+/CD38− cancer cells capable of initiating and promoting tumorigenesis in immunodeficient mice injected with cells derived from Acute Myeloid Leukemia (AML) patients (38). This evidence concerns the gene CD34 and acute myeloid leukemia.